Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 16,142 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Active, not recruiting Not applicable Interventional

Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

NCT04862117
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Aventura, Florida • Zephyrhills, Florida • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Active, not recruiting Not applicable Interventional

Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery

NCT05025020
View directory record Official record
Conditions
Breast Cancer
Interventions
interactive 3D tool, BREAST-Q Reconstruction Module, DQI, Ottawa Decision Regret Scale
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Not listed Phase 4 Interventional

Role of TXA in Patients Undergoing Breast Free Flap Reconstruction

NCT06428682
View directory record Official record
Conditions
Breast Cancer, Blood Loss, Surgical
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Nov 11, 2026, 5:53 AM EST
Recruiting Phase 2 Interventional

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NCT05136196
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
232
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 179 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow

NCT03456427
View directory record Official record
Conditions
Breast Cancer
Interventions
Patient-Assisted Compression (PAC), Technologist-Controlled (TC) Compression
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
40 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Nov 11, 2026, 5:53 AM EST
Completed No phase listed Observational

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT05230186
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Tumor Biopsy
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 1 Interventional

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

NCT02307240
View directory record Official record
Conditions
Triple-Negative Breast Cancer, High-grade Serous Ovarian Cancer, Solid Tumors, NUT Midline Carcinoma
Interventions
CUDC-907
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
16 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Nov 11, 2026, 5:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Turmeric and Curcumin on Sebum Production

NCT03066791
View directory record Official record
Conditions
Inflammation; Skin
Interventions
Turmeric tablets, Curcumin and Bioperine tablets, Placebo tablets
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Nov 11, 2026, 5:53 AM EST
Recruiting Phase 3 Interventional

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Cemiplimab, Standard of care
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Completed No phase listed Observational

The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases

NCT00005660
View directory record Official record
Conditions
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 11, 2026, 5:53 AM EST
Terminated Phase 1 Interventional

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

NCT03597282
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
NEO-PV-01, Nivolumab, Adjuvant, APX005M, ipilimumab
Biological · Other
Lead sponsor
BioNTech US Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Nov 11, 2026, 5:53 AM EST
Terminated No phase listed Observational Accepts healthy volunteers Results available

Automated Breast Ultrasound Case Collection Registry

NCT03417024
View directory record Official record
Conditions
Breast Cancer
Interventions
Automated Breast Ultrasound, Digital Breast Tomosynthesis
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

NCT06104124
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
37
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Skin Change Actions by Nursing

NCT06127524
View directory record Official record
Conditions
Pressure Injury
Interventions
SEM Scanner
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
4,733 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
7
States / cities
Kennett Square, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Terminated Not applicable Interventional Results available

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

NCT03626623
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 11, 2026, 5:53 AM EST
Active, not recruiting Not applicable Interventional

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

NCT02295059
View directory record Official record
Conditions
Breast Cancer
Interventions
omega 3 fatty acids
Dietary Supplement
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 11, 2026, 5:53 AM EST
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Nov 11, 2026, 5:53 AM EST
Completed Not applicable Interventional Results available

Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure

NCT03315286
View directory record Official record
Conditions
Skin Cancer, Actinic Keratoses, Ultraviolet-Induced Change in Normal Skin, Behavior, Health, Behavior, Risk Reduction
Interventions
SHADE Ultraviolet Sensor, Standard of care counseling
Device · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 1Phase 2 Interventional

Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00002786
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

NCT01232569
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab 162 mg, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Nov 11, 2026, 5:53 AM EST
Terminated Not applicable Interventional Results available

Personalized Interactive Laser Therapy of Port Wine Stain

NCT00782483
View directory record Official record
Conditions
Port Wine Stain
Interventions
ThermoVision A20M Infrared Camera, ScleroPLUS, 3D Digital Camera
Device
Lead sponsor
University of Arkansas
Other
Eligibility
3 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 2 Interventional Results available

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

NCT01323517
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Melphalan and Dactinomycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 2 Interventional

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

NCT00615940
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
WX-671, placebo
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Nov 11, 2026, 5:53 AM EST
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

NCT01438489
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • La Jolla, California • La Palma, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Nov 11, 2026, 5:53 AM EST